BCLSI
ANNX icon

Bain Capital Life Sciences Investors’s Annexon ANNX Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio ANNX Stock Details ANNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3M Sell
4,437,731
-774,943
-15% -$4.28M 1.51% 15
2026
Q1 		$28.9M Sell
5,212,674
-36,395
-0.7% -$205K 2.6% 9
2025
Q4 		$26.4M Hold
5,249,069
– – 2.02% 11
2025
Q3 		$16M Hold
5,249,069
– – 1.06% 14
2025
Q2 		$12.6M Hold
5,249,069
– – 1.58% 14
2025
Q1 		$10.1M Hold
5,249,069
– – 1.5% 12
2024
Q4 		$26.9M Sell
5,249,069
-3,200,679
-38% -$19.7M 3.17% 9
2024
Q3 		$50M Buy
8,449,748
+540
+0% +$3.2K 5.2% 7
2024
Q2 		$41.4M Sell
8,449,208
-254,060
-3% -$1.31M 4.55% 7
2024
Q1 		$62.4M Buy
8,703,268
+641,549
+8% +$3.33M 5.02% 8
2023
Q4 		$36.6M Buy
8,061,719
+2,359,793
+41% +$5.84M 3.51% 8
2023
Q3 		$13.5M Hold
5,701,926
– – 1.5% 18
2023
Q2 		$20.1M Buy
5,701,926
+815,310
+17% +$3.56M 2.07% 16
2023
Q1 		$18.8M Hold
4,886,616
– – 2.35% 16
2022
Q4 		$25.3M Buy
4,886,616
+1,284,690
+36% +$7.06M 2.82% 12
2022
Q3 		$22.3M Buy
3,601,926
+360,298
+11% +$1.95M 2.66% 14
2022
Q2 		$12.2M Hold
3,241,628
– – 1.43% 18
2022
Q1 		$8.85M Hold
3,241,628
– – 0.86% 22
2021
Q4 		$37.2M Hold
3,241,628
– – 2.95% 11
2021
Q3 		$60.3M Hold
3,241,628
– – 3.74% 10
2021
Q2 		$73M Hold
3,241,628
– – 4.78% 6
2021
Q1 		$90.2M Hold
3,241,628
– – 5.11% 5
2020
Q4 		$81.1M Hold
3,241,628
– – 5.09% 5
2020
Q3 		$98M Buy
+3,241,628
New +$76.1M 9.13% 3

Other funds holding ANNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Bain Capital Life Sciences Investors's ANNX Position: Q2 2026 in Review

Bain Capital Life Sciences Investors reduced its Annexon (ANNX) stake by 15% in Q2 2026, selling an estimated $4.28M and leaving 4,437,731 shares worth $25.3M. The position accounts for 1.51% of the portfolio, ranked #15.

Bain Capital Life Sciences Investors first reported a position in ANNX in Q3 2020 and has held it in 24 quarters since. The position peaked at $98M in Q3 2020. 216 funds tracked by Wall St. Rank hold ANNX as of Q2 2026.

  • Bain Capital Life Sciences Investors held 4,437,731 shares of Annexon worth $25.3M as of Q2 2026.
  • Bain Capital Life Sciences Investors sold 774,943 Annexon shares in Q2 2026, an estimated $4.28M.
  • Annexon made up 1.51% of Bain Capital Life Sciences Investors's portfolio in Q2 2026, its #15 holding.
  • Bain Capital Life Sciences Investors first reported a position in Annexon in Q3 2020 and has held it in 24 quarters since.
  • Bain Capital Life Sciences Investors's Annexon position peaked at $98M in Q3 2020.
  • 216 funds tracked by Wall St. Rank held Annexon as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.